论文部分内容阅读
目的:观察脂糖舒(ZTS)对2型糖尿病大鼠胰岛素抵抗的改善作用。方法:对2型糖尿病胰岛素抗性模型大鼠灌胃ZTS(1次/d),连续9周,同时以二甲双胍和格列齐特(达美康)及健康大鼠作对照,进行糖耐量试验,测定血浆葡萄糖(Glu)、胰岛素(Ins)、三酰甘油(TG)、游离脂肪酸(NEFA)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)含量,并称体质量和脂肪组织重量,计算胰岛素抵抗指数(IRI)。结果:脂糖舒、二甲双胍和格列齐特均能显著降低2型糖尿病大鼠(NIDDM大鼠)的高Ins、高Glu、高脂血症和降低IRI,升高HDL-c含量,抑制体质量和脂肪组织重量增长。其中,脂糖舒抑制病鼠体质量和脂肪组织质量增长以及降糖降脂(NEFA和LDL-c)和降IRI作用优于格列齐特(P<0.01或P<0.001)。与二甲双胍比较,脂糖舒降NEFA和TC作用较强(P<0.05),对其余指标包括降IRI作用与二甲双胍相当(P>0.05)且脂糖舒降IRI作用呈剂量依赖关系。结论:脂糖舒明显改善2型糖尿病的胰岛素抗性。
Objective: To observe the effect of ZTS on insulin resistance in type 2 diabetic rats. Methods: Type 2 diabetic insulin resistance model rats were intragastrically administered with ZTS (1 time / d) for 9 weeks. Metformin and gliclazide (M) and healthy rats were used as control. Glucose tolerance test Plasma glucose, insulin, triglyceride, free fatty acid (NEFA), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol -C) content, and weighed body mass and adipose tissue weight, calculated insulin resistance index (IRI). Results: Both Zhitoushu, metformin and gliclazide could significantly reduce high Ins, high Glu, hyperlipidemia and IRI, increase HDL-c content in type 2 diabetic rats (NIDDM rats) Mass and adipose tissue weight gain. Among them, Zhitangshu was superior to Gliclazide (P <0.01 or P <0.001) in suppressing body weight and adipose tissue mass, decreasing blood sugar and lipid (NEFA and LDL-c) and decreasing IRI in mice. Compared with metformin, NEFA and TC played a more important role (P <0.05), and the effects of other parameters, including lowering of IRI, were comparable to metformin (P> 0.05) and the effect of IRS on IRI was dose-dependent. Conclusion: Zhitangshu significantly improves insulin resistance in type 2 diabetic patients.